RU2017112518A - Пиридоновые и азапиридоновые соединения и способы применения - Google Patents
Пиридоновые и азапиридоновые соединения и способы применения Download PDFInfo
- Publication number
- RU2017112518A RU2017112518A RU2017112518A RU2017112518A RU2017112518A RU 2017112518 A RU2017112518 A RU 2017112518A RU 2017112518 A RU2017112518 A RU 2017112518A RU 2017112518 A RU2017112518 A RU 2017112518A RU 2017112518 A RU2017112518 A RU 2017112518A
- Authority
- RU
- Russia
- Prior art keywords
- compound according
- compound
- och
- heterocyclyl
- methyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 30
- -1 (1-methylazetidin-3-yl) oxy, N -methyl-N-oxetan-3-ylamino Chemical group 0.000 claims 11
- 125000001072 heteroaryl group Chemical group 0.000 claims 10
- 125000000623 heterocyclic group Chemical group 0.000 claims 10
- 125000003118 aryl group Chemical group 0.000 claims 7
- 125000004452 carbocyclyl group Chemical group 0.000 claims 6
- 125000002393 azetidinyl group Chemical group 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 125000003566 oxetanyl group Chemical group 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- JBXGNKZFIOAVNY-UHFFFAOYSA-N 2h-thieno[2,3-d]pyridazin-4-one Chemical compound O=C1N=NC=C2SCC=C12 JBXGNKZFIOAVNY-UHFFFAOYSA-N 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/62—Halogen-containing esters
- C07C69/65—Halogen-containing esters of unsaturated acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/04—Esters of boric acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Neurology (AREA)
- Otolaryngology (AREA)
- Biomedical Technology (AREA)
Claims (65)
1. Соединение, выбранное из формулы I:
или его стереоизомеры, таутомеры, или фармацевтически приемлемые соли, где:
R1 представляет собой Н, D, F, Cl, CN, -NH2, -NHCH3, -N(CH3)2, -OH, -OCH3, -ОСН2СН3, -ОСН2СН2ОН, гетероарил, выбранный из имидазолила и пиразолила, гетероциклил, выбранный из оксетанила и азетидинила, и С1-С3 алкил;
R2, R3 и R4 независимо выбраны из Н, D, F, Cl, -NH2, -NHCH3, -N(CH3)2, -ОН, -ОСН3, -ОСН2СН3, -ОСН2СН2ОН, и С1-С3 алкила;
R5 представляет собой необязательно замещенный С6-С20 арил, C3-C12 карбоциклил, С2-С20 гетероциклил, С1-С20 гетероарил, -(С6-С20 арил)-(С2-С20 гетероциклил), -(С1-С20 гетероарил)-(С2-С20 гетероциклил), -(C1-C20 гетероарил)-(С1-С6 алкил), или -(C1-C20 гетероарил)-С(=O)-(С2-С20 гетероциклил);
R6 представляет собой Н, F, -NH2, -ОН, или необязательно замещенный C1-C3 алкил;
X представляет собой S, S(=O), S(=O)2, N, NR6, О, или CR7;
R7 независимо выбран из Н, D, F, Cl, -СН3, -СН2СН3, -CN, -CH2F, -CHF2, -CF3, -NH2, -ОН, и -ОСН3;
Y1 и Y2 независимо выбраны из CR6 и N;
Z1, Z2, Z3, и Z4 независимо выбраны из С, CR7 и N;
Z5 представляет собой -CR3=N-;
один из Z1 и Z2, или X и Z1, где X не представляет собой S, S(=O), или S(=O)2, образуют пяти, шести, или семичленное арильное, карбоциклильное, гетероциклильное или гетероарильное кольцо;
где алкил, карбоциклил, гетероциклил, арил, и гетероарил необязательно замещены одной или более группой, независимо выбранной из D, F, Cl, Br, I, -СН3, -СН2СН3, -СН2СН(СН3)2, -СН2ОН, -СН2СН2ОН, -С(СН3)2ОН, -СН(ОН)СН(СН3)2, -С(СН3)2СН2ОН, -CH2CH2SO2CH3, -СН2ОР(O)(ОН)2, -CN, -CH2F, -CHF2, -CF3, -CO2H, -COCH3, -CO2CH3, -CO2C(СН3)3, -СОСН(ОН)СН3, -CONH2, -CONHCH3, -CON(CH3)2, -C(CH3)2CONH2, -NO2, -NH2, -NHCH3, -N(CH3)2, -NHCOCH3, -N(CH3)COCH3, -NHS(O)2CH3, -N(CH3)C(CH3)2CONH2, -N(CH3)CH2CH2S(O)2CH3, =O, -OH, -OCH3, -OCH2CH2N(CH3)2, -OP(O)(OH)2, -S(O)2N(CH3)2, -SCH3, -CH2OCH3, -S(O)2CH3, циклопропила, азетидинила, (1-метилазетидин-3-ил)окси, N-метил-N-оксетан-3-иламино, азетидин-1-илметила, оксетанила, и морфолино.
2. Соединение по п. 1, выбранное из формул Ia-c:
3. Соединение по п. 1, выбранное из формул Id-f:
4. Соединение по п. 1, выбранное из формул Ig-n:
5. Соединение по п. 1, выбранное из формул Io-t:
6. Соединение по п. 1, отличающееся тем, что Z1 и Z2 образуют пяти, шести, или семичленное арильное, карбоциклильное, гетероциклильное или гетероарильное кольцо, и выбрано из формул Iaa-ap:
7. Соединение по п. 1, отличающееся тем, что X и Z1, и X не представляет собой S, образуют пяти, шести, или семичленное арильное, карбоциклильное, гетероциклильное или гетероарильное кольцо, и выбрано из формул Iaq-bf:
8. Соединение по п. 1, отличающееся тем, что группа:
образует структуры:
при этом волнистая линия указывает на место присоединения.
9. Соединение по любому из пп. 1-8, отличающееся тем, что каждый из R1, R2, R3, и R4 представляет собой Н.
10. Соединение по п. 1, отличающееся тем, что R1 выбран из F, -СН3, -CH2F, -CHF2, и -CF3.
11. Соединение по п. 1, отличающееся тем, что R1 представляет собой -СН2ОН.
12. Соединение по п. 1, отличающееся тем, что R3 представляет собой F.
13. Соединение по п. 1, отличающееся тем, что R1 представляет собой -СН2ОН, каждый из R2 и R4 представляет собой Н, и R3 представляет собой F.
14. Соединение по п. 1, отличающееся тем, что R5 представляет собой необязательно замещенный С6-С20 арил, выбранный из фенила и нафтила.
15. Соединение по п. 1, отличающееся тем, что R5 представляет собой необязательно замещенный С3-С12 карбоциклил, выбранный из циклопропила, циклобутила, циклопентила, циклогексила, и циклогептила.
16. Соединение по п. 1, отличающееся тем, что R5 представляет собой необязательно замещенный С2-С20 гетероциклил, выбранный из оксетанила, азетидинила, пирролидинила, тетрагидрофурила, пиперидинила, пиперазинила, морфолинила, и тетрагидропиранила.
17. Соединение по п. 1, отличающееся тем, что R5 представляет собой необязательно замещенный C1-C20 гетероарил, выбранный из пиразолила, пиридинила, пиримидинила, 5-метил-4,5,6,7-тетрагидропиразоло[1,5-а]пиразин-2-ила, 5-ацетил-4,5,6,7-тетрагидропиразоло[1,5-а]пиразин-2-ила, 6,7-дигидро-4Н-пиразоло[5,1-с][1,4]оксазин-2-ила, и 1-метил-5-(5-(4-метилпиперазин-1-ил)пиридин-2-ила.
18. Соединение по п. 1, отличающееся тем, что R5 замещен одной или более группой, выбранной из F, Cl, -СН3, циклопропила, азетидинила, оксетанила, и морфолино.
19. Соединение по п. 1, отличающееся тем, что R5 выбран из структур:
при этом волнистая линия указывает на место присоединения.
20. Соединение по п. 1, отличающееся тем, что R6 представляет собой Н.
21. Соединение по п. 1, отличающееся тем, что X представляет собой S.
22. Соединение по п. 1, отличающееся тем, что X представляет собой N.
23. Соединение по п. 1, отличающееся тем, что X представляет собой CR7.
24. Соединение по п. 1, отличающееся тем, что Y1 представляет собой CR6 и Y2 представляет собой N.
25. Соединение по п. 1, отличающееся тем, что Y1 представляет собой N и Y2 представляет собой CR6.
26. Соединение по п. 1, отличающееся тем, что каждый из Y1 и Y2 представляет собой CR6.
27. Фармацевтическая композиция, содержащая соединение по п. 1 и фармацевтически приемлемый носитель, скользящее вещество, разбавитель, или наполнитель.
28. Фармацевтическая композиция по п. 27, дополнительно содержащая второй терапевтический агент.
29. Способ получения фармацевтической композиции, включающий объединение соединения по п. 1 с фармацевтически приемлемым носителем.
30. Соединение по п. 1, выбранное из
5-[5-фтор-2-(гидроксиметил)-3-(1-метил-5-{[5-(4-(оксетан-3-ил)пиперазин-1-ил)пиридин-2-ил]амино}-6-оксо-1,6-дигидропиридин-3-ил)фенил]-8-тиа-4,5-диазатрицикло[7.4.0.02,7]тридека-1(9),2(7),3-триен-6-он,
5-[5-фтор-2-(гидроксиметил)-3-(1-метил-5-{[5-(4-метилпиперазин-1-ил)пиридин-2-ил]амино}-6-оксо-1,6-дигидропиридин-3-ил)фенил]-8-тиа-4,5-диазатрицикло[7.4.0.02,7]тридека-1(9),2(7),3(4)-триен-6-он,
3-(5-фтор-2-гидроксиметил-3-{1-метил-5-[6-(4-метилпиперазин-1-ил)-пиридазин-3-иламино]-6-оксо-1,6-дигидропиридин-3-ил}-фенил)-6,7,8,9-тетрагидро-3Н-бензо[4,5]тиено[2,3-d]пиридазин-4-он,
3-(5-фтор-2-гидроксиметил-3-{1-метил-5-[6-(4-оксетан-3-ил-пиперазин-1-ил)-пиридазин-3-иламино]-6-оксо-1,6-дигидропиридин-3-ил}-фенил)-6,7,8,9-тетрагидро-3Н-бензо[4,5]тиено[2,3-d]пиридазин-4-он,
2-(5-фтор-2-(гидроксиметил)-3-(1-метил-5-(5-(4-(оксетан-3-ил)пиперазин-1-ил)пиридин-2-иламино)-6-оксо-1,6-дигидропиридин-3-ил)фенил)-6,7,8,9-тетрагидро-[1,2,4]триазино[4,5-а]индол-1(2Н)-он, и
2-(5-фтор-2-(гидроксиметил)-3-(1-метил-5-(5-(4-метилпиперазин-1-ил)пиридин-2-иламино)-6-оксо-1,6-дигидропиридин-3-ил)фенил)-6,7,8,9-тетрагидро-[1,2,4]триазино[4,5-а]индол-1(2Н)-он.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33235310P | 2010-05-07 | 2010-05-07 | |
US61/332,353 | 2010-05-07 | ||
US201161443952P | 2011-02-17 | 2011-02-17 | |
US61/443,952 | 2011-02-17 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2012152548A Division RU2617405C2 (ru) | 2010-05-07 | 2011-05-06 | Пиридоновые и азапиридоновые соединения и способы применения |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2017112518A true RU2017112518A (ru) | 2019-01-25 |
RU2017112518A3 RU2017112518A3 (ru) | 2020-07-22 |
Family
ID=44475130
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2017112518A RU2017112518A (ru) | 2010-05-07 | 2011-05-06 | Пиридоновые и азапиридоновые соединения и способы применения |
RU2012152548A RU2617405C2 (ru) | 2010-05-07 | 2011-05-06 | Пиридоновые и азапиридоновые соединения и способы применения |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2012152548A RU2617405C2 (ru) | 2010-05-07 | 2011-05-06 | Пиридоновые и азапиридоновые соединения и способы применения |
Country Status (20)
Country | Link |
---|---|
US (4) | US8618107B2 (ru) |
EP (1) | EP2566869B1 (ru) |
JP (1) | JP5832524B2 (ru) |
KR (2) | KR101954044B1 (ru) |
CN (3) | CN110818724B (ru) |
AR (1) | AR085683A1 (ru) |
AU (1) | AU2011249912A1 (ru) |
BR (1) | BR112012028530A2 (ru) |
CA (2) | CA3034600C (ru) |
ES (1) | ES2573716T3 (ru) |
HK (2) | HK1180326A1 (ru) |
IL (3) | IL222918B (ru) |
MX (1) | MX2012012975A (ru) |
MY (1) | MY160349A (ru) |
NZ (1) | NZ604004A (ru) |
RU (2) | RU2017112518A (ru) |
SG (1) | SG185462A1 (ru) |
TW (1) | TWI503319B (ru) |
WO (1) | WO2011140488A1 (ru) |
ZA (1) | ZA201209205B (ru) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2011249912A1 (en) * | 2010-05-07 | 2012-11-29 | Genentech, Inc. | Pyridone and aza-pyridone compounds and methods of use |
EP2593107A1 (en) * | 2010-07-12 | 2013-05-22 | Merck Sharp & Dohme Corp. | Tyrosine kinase inhibitors |
CN103201277B (zh) * | 2010-09-01 | 2015-11-25 | 吉利德康涅狄格有限公司 | 哒嗪酮、其制备方法及使用方法 |
US9249123B2 (en) * | 2010-09-01 | 2016-02-02 | Genentech, Inc. | Pyridinones/pyrazinones, method of making, and method of use thereof |
AR088642A1 (es) * | 2011-11-03 | 2014-06-25 | Genentech Inc | Compuestos de piperazina alquilados |
CA2852964A1 (en) | 2011-11-03 | 2013-05-10 | F. Hoffmann-La Roche Ag | Bicyclic piperazine compounds |
UA111756C2 (uk) * | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
WO2013067264A1 (en) | 2011-11-03 | 2013-05-10 | Genentech, Inc. | 8-fluorophthalazin-1 (2h) - one compounds as inhibitors of btk activity |
WO2013161848A1 (ja) * | 2012-04-27 | 2013-10-31 | カルナバイオサイエンス株式会社 | 新規1,2,4-トリアジン誘導体 |
CN104704129A (zh) | 2012-07-24 | 2015-06-10 | 药品循环公司 | 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变 |
CA2891634A1 (en) | 2012-11-30 | 2014-06-05 | F. Hoffmann-La Roche Ag | Inhibitors of bruton's tyrosine kinase |
WO2014108820A1 (en) * | 2013-01-08 | 2014-07-17 | Aurigene Discovery Technologies Limited | Substituted 2-pyrazinone derivatives as kinase inhibitors |
US11039617B2 (en) | 2013-01-30 | 2021-06-22 | Agrofresh Inc. | Large scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness |
US10070649B2 (en) | 2013-01-30 | 2018-09-11 | Agrofresh Inc. | Volatile applications against pathogens |
WO2014125410A1 (en) * | 2013-02-12 | 2014-08-21 | Aurigene Discovery Technologies Limited | N-substituted heterocyclic derivatives as kinase inhibitors |
DK2989106T3 (en) | 2013-04-25 | 2017-03-20 | Beigene Ltd | CONDENSED HETEROCYCLIC COMPOUNDS AS PROTEINKINASE INHIBITORS |
US9326985B2 (en) | 2013-07-03 | 2016-05-03 | Genentech, Inc. | Heteroaryl pyridone and aza-pyridone amide compounds |
CN107011441B (zh) | 2013-09-13 | 2020-12-01 | 百济神州(广州)生物科技有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
JP6275846B2 (ja) * | 2013-12-05 | 2018-02-07 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 求電子性官能基を有するヘテロアリールピリドン及びアザ−ピリドン化合物 |
KR102003754B1 (ko) | 2014-07-03 | 2019-07-25 | 베이진 엘티디 | Pd-l1 항체와 이를 이용한 치료 및 진단 |
CN111303159A (zh) | 2014-10-02 | 2020-06-19 | 豪夫迈·罗氏有限公司 | 用于治疗由布鲁顿酪氨酸激酶(btk)介导的疾病的吡唑甲酰胺化合物 |
EP3212645B1 (en) | 2014-10-27 | 2018-11-28 | F.Hoffmann-La Roche Ag | Process for making tricyclic lactam compounds |
EP3253753A4 (en) | 2015-01-20 | 2018-06-27 | Xoc Pharmaceuticals, Inc | Ergoline compounds and uses thereof |
US9676776B2 (en) | 2015-01-20 | 2017-06-13 | Xoc Pharmaceuticals, Inc. | Isoergoline compounds and uses thereof |
MX2018010010A (es) * | 2016-02-19 | 2018-11-09 | Novartis Ag | Compuestos tetraciclicos de piridona como antivirales. |
JP6577143B2 (ja) | 2016-02-29 | 2019-09-18 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ブルトンチロシンキナーゼの阻害剤を含む剤形組成物 |
RS64770B1 (sr) | 2016-03-07 | 2023-11-30 | Agrofresh Inc | Sinergistički postupci upotrebe jedinjenja benzoksaborola i gasova za prezerviranje kao antimikrobnih agenasa za useve |
CN108473510B (zh) * | 2016-04-28 | 2021-10-29 | 豪夫迈·罗氏有限公司 | 制备2-吡唑并[1,5-a]吡嗪-2-基吡啶并[1,2-a]嘧啶-4-酮的方法 |
CN109475536B (zh) | 2016-07-05 | 2022-05-27 | 百济神州有限公司 | 用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合 |
JP7402685B2 (ja) | 2016-08-16 | 2023-12-21 | ベイジーン スウィッツァーランド ゲーエムベーハー | (s)-7-(1-アクリロイルピペリジン-4-イル)-2-(4-フェノキシフェニル)-4,5,6,7-テトラ-ヒドロピラゾロ[1,5-a]ピリミジン-3-カルボキサミドの結晶形、その調製、及びその使用 |
WO2018033135A1 (en) | 2016-08-19 | 2018-02-22 | Beigene, Ltd. | Use of a combination comprising a btk inhibitor for treating cancers |
WO2018053437A1 (en) | 2016-09-19 | 2018-03-22 | Mei Pharma, Inc. | Combination therapy |
WO2018109050A1 (en) * | 2016-12-15 | 2018-06-21 | F. Hoffmann-La Roche Ag | Process for preparing btk inhibitors |
EP3573989A4 (en) | 2017-01-25 | 2020-11-18 | Beigene, Ltd. | CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) -PIPERIDINE-4-YL) -2- (4-PHENOXYPHENYL) -4,5,6,7-TETRAHYDROPYRAZOLO [1,5-A ] PYRIMIDINE-3-CARBOXAMIDE, MANUFACTURING AND USES THEREOF |
KR102398659B1 (ko) * | 2017-03-17 | 2022-05-16 | 주식회사 대웅제약 | 카이네이즈 저해제로서의 피롤로트리아진 유도체 |
AU2018275873A1 (en) | 2017-06-01 | 2019-12-19 | Xoc Pharmaceuticals, Inc. | Ergoline derivatives for use in medicine |
EP3645569A4 (en) | 2017-06-26 | 2021-03-24 | BeiGene, Ltd. | IMMUNOTHERAPY FOR LIVER CELL CARCINOMA |
US11377449B2 (en) | 2017-08-12 | 2022-07-05 | Beigene, Ltd. | BTK inhibitors with improved dual selectivity |
JP7100125B2 (ja) | 2017-10-27 | 2022-07-12 | フレゼニウス・カビ・オンコロジー・リミテッド | リボシクリブおよびその塩の改善された調製のためのプロセス |
TWI694995B (zh) * | 2017-11-06 | 2020-06-01 | 美商美國禮來大藥廠 | Btk抑制劑化合物 |
MX2020005405A (es) * | 2017-11-24 | 2020-08-13 | Novartis Ag | Derivados de piridinona y su uso como inhibidores selectivos de alk-2. |
WO2019108795A1 (en) | 2017-11-29 | 2019-06-06 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors |
US11100492B2 (en) * | 2018-02-19 | 2021-08-24 | Peter Garrett | General purpose re-loadable card aggregation implementation |
WO2020081450A1 (en) | 2018-10-15 | 2020-04-23 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
EP3930717A1 (en) * | 2019-02-25 | 2022-01-05 | Guangzhou Lupeng Pharmaceutical Company Ltd. | Inhibitor of btk and mutants thereof |
WO2020210508A1 (en) | 2019-04-09 | 2020-10-15 | Nurix Therapeutics, Inc. | 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus |
MX2021013751A (es) | 2019-05-17 | 2022-01-26 | Nurix Therapeutics Inc | Compuestos de ciano ciclobutilo para la inhibicion del protooncogen b de linfoma de linaje b de casitas (cbl-b) y usos de los mismos. |
WO2021030091A1 (en) * | 2019-08-09 | 2021-02-18 | The Regents Of The University Of California | Compositions and methods for treating metabolic disease |
US20220363689A1 (en) * | 2019-10-05 | 2022-11-17 | Newave Pharmaceutical Inc. | Inhibitor of btk and mutants thereof |
US20230322715A1 (en) * | 2019-10-14 | 2023-10-12 | The Regents Of The University Of California | Broad spectrum anti-cancer compounds |
WO2021091575A1 (en) * | 2019-11-08 | 2021-05-14 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
EP4069237A1 (en) | 2019-12-04 | 2022-10-12 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
WO2021164735A1 (en) | 2020-02-20 | 2021-08-26 | Hutchison Medipharma Limited | Heteroaryl heterocyclic compounds and uses thereof |
WO2021183980A1 (en) | 2020-03-13 | 2021-09-16 | Fmc Corporation | Substituted pyrimidines and triazines as herbicides |
CN115715291A (zh) * | 2020-06-18 | 2023-02-24 | 上海华汇拓医药科技有限公司 | 布鲁顿酪氨酸激酶抑制剂及其制备方法 |
TW202220998A (zh) | 2020-09-21 | 2022-06-01 | 大陸商和記黃埔醫藥(上海)有限公司 | 雜芳基雜環化合物及其用途 |
US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
TW202334089A (zh) | 2021-11-02 | 2023-09-01 | 美商夫雷爾醫療公司 | Pparg反向激動劑及其用途 |
CN114751910B (zh) * | 2022-05-17 | 2023-02-24 | 重庆文理学院 | 一种可诱导细胞巨泡式死亡的化合物及其制备方法和应用 |
US11786531B1 (en) | 2022-06-08 | 2023-10-17 | Beigene Switzerland Gmbh | Methods of treating B-cell proliferative disorder |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
BR0211073A (pt) | 2001-07-12 | 2004-12-14 | Avecia Ltd | Sistema de catalisador, e, processos para a preparação de um catalisador microencapsulado, de bifenilas opcionalmente substituìdas, de alcenos opcionalmente substituìdos, de um produto hidrogenado e de dióis |
RU2418788C2 (ru) * | 2005-03-10 | 2011-05-20 | Сги Фармасьютиклз, Инк. | Некоторые замещенные амиды, способ их получения и способ их применения |
ATE504565T1 (de) | 2005-10-07 | 2011-04-15 | Exelixis Inc | Azetidine als mek-inhibitoren bei der behandlung proliferativer erkrankungen |
CN101437820A (zh) * | 2006-03-07 | 2009-05-20 | 阿雷生物药品公司 | 杂二环吡唑化合物和使用方法 |
BRPI0713736A2 (pt) * | 2006-06-20 | 2014-11-18 | Hoffmann La Roche | Derivados de tetralina e indano e emprego destes |
AR063706A1 (es) * | 2006-09-11 | 2009-02-11 | Cgi Pharmaceuticals Inc | Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden. |
EP2079729A1 (en) * | 2006-11-03 | 2009-07-22 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
CL2008002793A1 (es) | 2007-09-20 | 2009-09-04 | Cgi Pharmaceuticals Inc | Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras |
JP5587193B2 (ja) * | 2007-10-23 | 2014-09-10 | エフ.ホフマン−ラ ロシュ アーゲー | 新規なキナーゼ阻害剤 |
ES2420846T3 (es) * | 2008-02-05 | 2013-08-27 | F. Hoffmann-La Roche Ag | Nuevas piridinonas y piridazinonas |
EP2297105B1 (en) * | 2008-05-06 | 2015-09-02 | Gilead Connecticut, Inc. | Substituted amides, method of making, and use as btk inhibitors |
PE20100851A1 (es) | 2008-06-24 | 2011-01-31 | Hoffmann La Roche | PIRIDIN-2-ONAS Y PIRIDAZIN-3-ONAS SUSTITUIDAS COMO INHIBIDORES DE Btk |
EP2300459B1 (en) | 2008-07-02 | 2013-05-29 | F. Hoffmann-La Roche AG | Novel phenylpyrazinones as kinase inhibitors |
AU2011249912A1 (en) | 2010-05-07 | 2012-11-29 | Genentech, Inc. | Pyridone and aza-pyridone compounds and methods of use |
-
2011
- 2011-05-06 AU AU2011249912A patent/AU2011249912A1/en not_active Abandoned
- 2011-05-06 AR ARP110101574A patent/AR085683A1/es active IP Right Grant
- 2011-05-06 US US13/102,720 patent/US8618107B2/en active Active
- 2011-05-06 CN CN201911154122.5A patent/CN110818724B/zh active Active
- 2011-05-06 MY MYPI2012004877A patent/MY160349A/en unknown
- 2011-05-06 NZ NZ604004A patent/NZ604004A/en not_active IP Right Cessation
- 2011-05-06 TW TW100116060A patent/TWI503319B/zh not_active IP Right Cessation
- 2011-05-06 BR BR112012028530A patent/BR112012028530A2/pt not_active IP Right Cessation
- 2011-05-06 CN CN201180033536.8A patent/CN103038233B/zh active Active
- 2011-05-06 RU RU2017112518A patent/RU2017112518A/ru not_active Application Discontinuation
- 2011-05-06 KR KR1020187014598A patent/KR101954044B1/ko active IP Right Grant
- 2011-05-06 CA CA3034600A patent/CA3034600C/en not_active Expired - Fee Related
- 2011-05-06 WO PCT/US2011/035596 patent/WO2011140488A1/en active Application Filing
- 2011-05-06 JP JP2013509305A patent/JP5832524B2/ja active Active
- 2011-05-06 CA CA2798634A patent/CA2798634C/en not_active Expired - Fee Related
- 2011-05-06 CN CN201710450858.1A patent/CN107253963B/zh active Active
- 2011-05-06 ES ES11731170.4T patent/ES2573716T3/es active Active
- 2011-05-06 KR KR1020127032195A patent/KR101862327B1/ko active IP Right Grant
- 2011-05-06 RU RU2012152548A patent/RU2617405C2/ru active
- 2011-05-06 SG SG2012082178A patent/SG185462A1/en unknown
- 2011-05-06 MX MX2012012975A patent/MX2012012975A/es active IP Right Grant
- 2011-05-06 EP EP11731170.4A patent/EP2566869B1/en active Active
-
2012
- 2012-11-07 IL IL22291812A patent/IL222918B/en active IP Right Grant
- 2012-12-05 ZA ZA2012/09205A patent/ZA201209205B/en unknown
-
2013
- 2013-06-28 HK HK13107639.7A patent/HK1180326A1/zh unknown
- 2013-10-22 US US14/059,626 patent/US9505785B2/en active Active
-
2016
- 2016-09-30 US US15/281,923 patent/US10053469B2/en active Active
-
2018
- 2018-02-26 US US15/905,363 patent/US10344040B2/en active Active
- 2018-03-02 HK HK18103049.5A patent/HK1243417A1/zh unknown
- 2018-12-18 IL IL263780A patent/IL263780A/en unknown
-
2019
- 2019-10-07 IL IL26985819A patent/IL269858A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2017112518A (ru) | Пиридоновые и азапиридоновые соединения и способы применения | |
JP2012525395A5 (ru) | ||
KR20190046921A (ko) | 세포 대사 과정의 억제제 | |
JP2017535561A5 (ru) | ||
KR102007056B1 (ko) | 과증식성 질환 치료시 Bub1 키나제 저해제로 사용하기 위한 치환된 벤질인다졸 | |
KR102319857B1 (ko) | P2x7 조절제 | |
JP2012512887A5 (ru) | ||
JP2017125037A (ja) | イミダゾピロリジノン化合物 | |
RU2017121278A (ru) | Триазоло-пиразинильные производные, применимые в качестве растворимых активаторов гуанилатциклазы | |
JP2016522232A5 (ru) | ||
HRP20151398T1 (hr) | Tricikliäśni derivati amina kao inhibitori protein tirozin kinaze | |
KR20170069199A (ko) | 섬유 아세포 성장 인자 수용체 키나아제 억제제인 인다졸계 화합물 및 이의 제조와 응용 | |
JP2004525149A5 (ru) | ||
JP2010540458A5 (ru) | ||
RU2018104702A (ru) | Новые соединения пирролопиримидина в качестве ингибиторов протеинкиназ | |
JP2019514878A5 (ru) | ||
RU2014105169A (ru) | 2-пиридилзамещенные имидазолы в качестве ингибиторов alk5 и/или alk4 | |
JP2011507854A5 (ru) | ||
RU2018134981A (ru) | Конъюгаты, содержащие ингибиторы RIPK2 | |
JP2011510995A5 (ru) | ||
RU2014118677A (ru) | Ингибиторы киназ типа polo | |
RU2016101548A (ru) | Соединения амидов гетероарилпиридона и азапиридона | |
JP2018505903A5 (ru) | ||
AU2019220064A1 (en) | Heterocyclic compound, application thereof and pharmaceutical composition comprising same | |
JP6726681B2 (ja) | Phd阻害剤としての縮合二環式ヘテロアリール誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20210609 |